A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

Key facts

Study ID

NCT06746402

Run by

Bristol-Myers Squibb

People needed

42

Starts

2025-02-10

Expected to finish

2025-09-11

Last updated by the study team

2025-10-06

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Female individuals not of childbearing potential (INOCBP) and males.
• Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments.
• Body mass index (BMI) 18.0 to 32.0 kg/m2 , inclusive, for Parts A and B.

You may not qualify if…

• Any significant acute or chronic medical illness as determined by the investigator.
• History of clinically relevant cardiac disease as determined by the investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for ventricular arrhythmias.
• Any significant history of disease of the cardiovascular system that in the opinion of the Investigator makes the participant unsuitable for enrollment into the study.
• Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• ICON San Antonio — San Antonio, Texas, United States
• Local Institution - 0001 — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.